HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 279, Issue 15, 14488-14495, April 9, 2004

This Article Abstract Full Text (PDF) All Versions of this Article: 279/15/14488    most recent M309355200v2 M309355200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harada, K. Articles by Potter, J. D. Search for Related Content PubMed PubMed Citation Articles by Harada, K. Articles by Potter, J. D. Social Bookmarking                      What's this?

Familial Hypertrophic Cardiomyopathy Mutations from Different Functional Regions of Troponin T Result in Different Effects on the pH and Ca²+ Sensitivity of Cardiac Muscle Contraction^*

Keita Harada and James D. Potter

From the Department of Molecular and Cellular Pharmacology, University of Miami School of Medicine, Miami, Florida 33101

Received for publication, August 25, 2003 , and in revised form, December 22, 2003.

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
To understand the molecular function of troponin T (TnT) in the Ca²⁺ regulation of muscle contraction as well as the molecular pathogenesis of familial hypertrophic cardiomyopathy (FHC), eight FHC-linked TnT mutations, which are located in different functional regions of human cardiac TnT (HCTnT), were produced, and their structural and functional properties were examined. Circular dichroism spectroscopy demonstrated different secondary structures of these TnT mutants. Each of the recombinant HCTnTs was incorporated into porcine skinned fibers along with human cardiac troponin I (HCTnI) and troponin C (HCTnC), and the Ca²⁺ dependent isometric force development of these troponin-replaced fibers was determined at pH 7.0 and 6.5. All eight mutants altered the contractile properties of skinned cardiac fibers. E244D potentiated the maximum force development without changing Ca²⁺ sensitivity. In contrast, the other seven mutants increased the Ca²⁺ sensitivity of force development but not the maximal force. R92L, R92W, and R94L also decreased the change in Ca²⁺ sensitivity of force development observed on lowering the pH from 7 to 6.5, when compared with wild type TnT. The examination of additional mutants, H91Q and a double mutant H91Q/R92W, suggests that mutations in a region including residues 91–94 in HCTnT can perturb the proper response of cardiac contraction to changes in pH. These results suggest that different regions of TnT may contribute to the pathogenesis of TnT-linked FHC through different mechanisms.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Vertebrate striated muscles contract in response to increasing intracellular Ca²⁺ concentration where Ca²⁺-bound troponin (Tn)¹ together with tropomyosin (Tm) activates the thin filaments and leads to interactions between the thick and thin filaments (1, 2). Tn, one of the regulatory proteins of striated muscle, is composed of three subunits, a Ca²⁺ binding subunit troponin C (TnC), an inhibitory subunit troponin I (TnI), and a Tm binding subunit troponin T (TnT). Although the activation and inhibition of muscle contraction are primarily achieved by TnC and TnI, respectively, these events cannot occur without TnT. In other words TnT not only anchors the Tn complex to the thin filament but also contributes to the Ca²⁺-dependent regulation of muscle contraction (3). Therefore, any functional and structural defects in these Tn subunits may cause alteration of the Ca²⁺ regulation of muscle contraction.

Familial hypertrophic cardiomyopathy (FHC) is an autosomal dominant disorder of heart muscle, is genetically heterogeneous, and results from mutations in genes encoding almost every major sarcomeric protein, including -myosin heavy chain (4), ventricular myosin essential and regulatory light chains (5), myosin-binding protein C (6, 7), -cardiac actin (8), -Tm (9), TnT (9), TnI (10), TnC, (11), and titin (12). The phenotype of FHC patients who carry these sarcomeric protein mutations appears to vary, from mild to remarkable hypertrophy, asymptomatic to severe symptoms such as chest pain, dyspnea, or arrhythmia and in some cases is associated with sudden cardiac death (SCD) (13).

To date there are at least 26 known mutations in the human cardiac TnT (HCTnT) gene that are linked to FHC, including 23 missense mutations, one deletion mutation, and one splicing donor site mutation (14). Patients who have TnT mutations often show no or mild hypertrophy, myocardial disarray, and have a malignant phenotype associated with a high incidence of SCD compared with the other FHC genes (15). These phenotypes, however, that are caused by the different TnT mutations, can vary, and the phenotype-genotype correlation is not currently fully understood. Many studies have been attempted to exploit the molecular pathogenesis of FHC caused by each TnT mutation from molecular to physiological levels and have shown that most FHC-TnT mutations alter the contractile properties of cardiac muscle, especially the Ca²⁺ sensitivity of force development and ATPase activity in vitro and in vivo (14, 16, 17). Our previous studies have demonstrated that the FHC-TnT mutants I79N, R92Q, F110I, E163K, and R278C increased Ca²⁺ sensitivity of force development when they were incorporated into porcine skinned cardiac fibers together with human CTnI and CTnC (18). Moreover, our transgenic mouse model, expressing the I79N mutation, has demonstrated similar properties (i.e. increase in the Ca²⁺ sensitivity of force development and ATPase activity) as well as other phenotypic properties of FHC, such as impaired diastolic function (19, 20). Similar results have been seen at both the molecular and physiological levels, implying that altered Ca²⁺ regulation of muscle contraction by TnT mutations might be the primary mechanism for TnT-linked FHC.

To further characterize the functional consequences of the FHC-TnT mutations on muscle contraction we have examined eight different HCTnT mutations, R92L, R92W, R94L, A104V, R130C, E163R, S179F, and E244D. They are located in functionally and structurally different regions of the HCTnT molecule. R92W, R94L, and A104V were shown to cause a severe form of FHC characterized by a high incidence of SCD (15, 21–23). S179F has a relatively mild or benign phenotype (24). However, a rare homozygous S179F mutation had a malignant prognosis. The R92L mutation has been linked to a severe phenotype, with a higher level of hypertrophy but less SCD, although the incidence of disease-related death is high (15, 25). There are insufficient clinical data for R130C, E163R, and E244D; therefore, the phenotypic features caused by these mutations are unclear (26, 27). To investigate effects of these TnT mutations, recombinant HCTnT mutants were incorporated into porcine cardiac skinned fibers together with HCTnI and HCTnC using the Tn displacement method followed by the measurement of Ca²⁺-dependent isometric force development at pH 7.0 and 6.5. Circular dichroism (CD) spectroscopy was utilized to determine the secondary structural variations among the isolated TnT mutations. Results from fiber studies have shown a correlation between the location of the FHC mutation in the TnT molecule and its effect on Ca²⁺-regulated force. Mutations near the N terminus of TnT seemed to impair its affinity for Tm, whereas mutations in the middle and near the C-terminal end of the molecule altered steady state cross-bridge kinetics. Nevertheless, most mutants showed similar effects on Ca²⁺-dependent force development, resulting in increased Ca²⁺ sensitivity. These results suggest that different TnT mutations alter the Ca²⁺ regulation of muscle contraction through different mechanisms and that these differences may contribute to the molecular pathogenesis of various forms of FHC caused by the TnT mutations.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Cloning and Mutagenesis of Human Cardiac Troponin cDNAs— Cloning of wild-type (WT) human cardiac TnT, TnI, and TnC was described elsewhere (18). To create the FHC-TnT mutations R92L, R92W, R94L, A104V, R130C, E163R, S179F, and E244D as well as the additional TnT mutations H91Q and H91Q/R92W, a sequential overlapping polymerase chain reaction-based method was utilized, and all clones were constructed in the pET-3d expression vector. Mutations in the TnT cDNA were confirmed by DNA sequencing.

Expression and Purification of Recombinant Human Cardiac Troponin—Recombinant human cardiac Tn subunits were expressed in Escherichia coli strain BL21 (DE3), and standard methods were used for the purification of the HCTnTs, HCTnI, and HCTnC (18). Briefly, recombinant HCTnTs were purified from a sonicated bacterial cell suspension using a Fast Flow S-Sepharose ion exchange column followed by Q-Sepharose column chromatography. Depending on the purity, the samples were further purified using a DE-52 column. TnTs were eluted with a 0- 0.6 M NaCl gradient in a buffer containing 20 mM citric acid (pH 7.0), 6 M urea, 2 mM EDTA, 1 mM dithiothreitol for the S-Sepharose column, a 0–0.5 M NaCl gradient in a buffer containing 20 mM Tris-HCl (pH 7.8), 6 M urea, 1 mM EDTA, 1 mM dithiothreitol for the Q-Sepharose column, and 0–0.3 M KCl in a buffer containing Tris-HCl (pH 8.0), 6 M urea, 1 mM EDTA, 1 mM dithiothreitol gradient for the DE-52 column.

Circular Dichroism of HCTnT Mutants—The CD spectra of HCTnT WT and the mutants were collected using a Jasco J-720 spectropolarimeter with a cell path length of 0.1 cm at ambient temperature (20 °C). Samples were dialyzed against 10 mM phosphate buffer (pH 7.0), including 0.5 or 0.3 M NaF. The concentrations of the HCTnT mutants were determined using the Bradford assay with wild type HCTnT (WT) as a standard. The final protein concentration was set to 0.25 mg/ml. Analysis and processing of data were carried out using the Jasco system software (Windows Standard Analysis, Version 1.20). Ten scans were averaged, and the spectrum of the buffer was subtracted for a base-line offset.

Mean residue ellipticity ([]_MRE, in degrees·cm²·dmol^–1) for the spectra were calculated using the equation []_MRE = []/(10·Cr·l), where [] is the measured ellipticity in millidegrees, Cr is the mean residue molar concentration, and l is the path length in cm. The -helical content for each sample was calculated using the standard equation for [] at 222 nm (28), []₂₂₂ =–30,300_fH – 2340, where f_H is the fraction of -helical content (f_H x 100, expressed in %).

Preparation of Porcine Skinned Cardiac Fibers and Measurement of Force Development—Skinned papillary muscles were prepared from the left ventricles of pig hearts. Small bundles of fibers were isolated and treated with the relaxing solution (10^–8 M Ca²⁺, 1 mM Mg²⁺, 7 mM EGTA, 5 mM MgATP, 20 mM imidazole (pH 7.0), 20 mM creatine phosphate, and 15 units/ml creatine phosphokinase, I = 150 mM) containing 1% Triton X-100 for 1 h and relaxing solution including 50% glycerol at –20 °C. For measurement of force development, small fibers (120 µm in diameter) were dissected and then mounted between a force transducer and a fixed needle. Fibers were skinned with 1% Triton X-100 in relaxing solution for 30 min at room temperature. After maximum force was measured at pCa 4 the fibers were exposed to increasing Ca²⁺ concentration ranging from pCa 8 to pCa 4, and the force-pCa relationship was recorded at pH 7.0 and then at pH 6.5 on the same fiber. The data were analyzed with the Hill equation as described previously (18).

Tn Displacement and Reconstitution in Skinned Cardiac Fibers— The Tn displacement/replacement method, which we have modified from that of Hatakenaka and Ohtsuki (29), was utilized to replace the Tn present in the porcine fibers with human subunits (18, 29). After the control Ca²⁺-dependent force development was measured the fibers were incubated with an excess amount of WT or HCTnT mutants (0.8 or 1.0 mg/ml) in a solution containing 250 mM KCl, 20 mM MES-KOH (pH 6.2), 5 mM MgCl₂, 5 mM EGTA, and 0.5 mM dithiothreitol for 1 h. Fibers were then incubated in the same, fresh TnT solution for another hour. Displaced fibers were washed with the same solution without protein and tested for Ca²⁺-unregulated force at pCa 8 and pCa 4. This Ca²⁺-unregulated force development is due to the absence of the endogenous porcine TnI and TnC. To evaluate the extent of exchange by different TnT mutants the equation %Ca²⁺ regulation = (F_{pCa 4} – F_{pCa 8})/F_{pCa 4} x 100 was employed, where F_{pCa 8} and F_{pCa 4} are the force development of TnT-displaced fibers at pCa 8 and pCa 4, respectively (see Fig. 1). F_{pCa 4} of the TnT mutants-reconstituted fibers was also compared with that of HCTnT WT-incorporated fibers for the direct effect of TnT mutations on isometric force development. After TnT-displaced fibers were incubated with an HCTnI·C complex for 1.5 h, Ca²⁺-dependent force development of Tn-displaced fibers was determined at pH 7.0 and then at pH 6.5.

View larger version (20K): [in this window] [in a new window]   FIG. 1. Tn displacement in porcine skinned cardiac fibers. Experimental protocol for isometric force development and TnT treatment followed by TnI·TnC reconstitution is shown. Treatment with HCTnT for 2h at room temperature resulted in a loss of the Ca2+-dependent regulation of force development. Subsequent TnI·C reconstitution recovered the Ca2+ sensitivity of force development.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Ionic Strength Dependent Stability of the Secondary Structure of Human Cardiac TnT Mutants—CD spectra of isolated HCTnT mutants were collected in the presence of 0.5 M NaF (Fig. 2). The estimated -helical content of WT TnT was 38%. Both of the Arg to Leu mutations, R92L and R94L, resulted in increased -helical content to 60 and 59%, respectively (Fig. 2). R92W, A104V, R130C, and E163K also showed increased -helical content, whereas the -helical content of S179F and E244D were similar to that of WT. In the presence of 0.3 M NaF, all TnTs, especially A104V, showed less -helical content compared with 0.5 M NaF (data not shown).

View larger version (22K): [in this window] [in a new window]   FIG. 2. Far-UV circular dichroism spectra of HCTnT WT and mutants. The secondary structure of the TnT mutants and WT in the presence of 0.5 M NaF were measured by CD spectroscopy. A, far-UV CD spectra of WT (open circles), R92L (closed triangles), and R92W (closed squares). B, far-UV CD spectra of WT (open circles), R94L (closed triangles), and R130C (closed squares). C, far-UV CD spectra of WT (open circles), A104V (closed triangles), and E163R (closed squares).

View larger version (16K): [in this window] [in a new window]   FIG. 3. Effect of mutants on the maximum isometric force development before and after TnI·TnC reconstitution. The maximum force development of skinned fibers measured after each TnT treatment (black bar) was compared with the maximum force of the same fibers but after being reconstituted with the TnI·TnC complex (white bar). Those values from TnT mutants-treated fibers were also compared with that of WT-treated fibers. *, p < 0.05; **, p < 0.01; ***, p < 0.001 (paired t test).

View larger version (14K): [in this window] [in a new window]   FIG. 4. pCa-force relationship of HCTnT WT on FHC mutants reconstituted fibers at pH 7.0. After TnT-treated fibers were reconstituted with the TnI·TnC complex, the Ca2+ dependent of force development of these fibers was increased at pH 7.0. Every panel contains the pCa-force curve of WT-reconstituted fibers (open circles) as a reference, and each panel represents the pCa-force relationship for the following mutant-treated fibers; A, R92L (triangles), R92W (inverted triangles) and R94L (squares); B, A104V (triangles) and R130C (squares); C, E163R (triangles), S179F (inverted triangles), and E244D (dot in squares and dashed lines).

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
A number of studies has been attempted to elucidate the molecular mechanisms of Ca²⁺ regulation of muscle contraction. However, the molecular function of TnT is not understood as well as that of TnC or TnI. At least 26 different mutations in the HCTnT gene have been identified (14) since Thierfelder et al. (9) reported the first FHC-related TnT mutations in 1994. Because FHC that is caused by TnT mutations might be a consequence of an altered molecular function of TnT, that would lead to abnormal cardiac muscle contraction, the functional analyses of these disease-causing TnT mutations could help our understanding of the molecular function of TnT as well as the pathogeneses of FHC. Lin et al. (34) first reported the functional consequences of FHC-I79N TnT mutation in 1996, and then Morimoto et al. (32) found that the FHC-TnT mutants, I79N and R92Q, increased Ca²⁺ sensitivity of isometric force development of skinned cardiac fibers when they were exchanged with the endogenous Tn complex. Since then many studies including those from our lab demonstrates that FHC-TnT mutants can alter Ca²⁺ regulation of muscle contraction (14, 16, 17). In this study we have also observed that all eight FHC-TnT mutants examined (i.e. R92L, R92W, R94L, A104V, R130C, E163R, S179F, and E244D) altered the contractile properties of skinned cardiac fibers in various ways. E244D potentiated the maximum force development without changing Ca²⁺ sensitivity, whereas the other seven mutants increased Ca²⁺ sensitivity but not maximal force development. Our results may lead to an understanding of why different mutations in TnT can cause the same pathological disease, i.e. FHC. We suggest that the altered Ca²⁺ regulation of force production could be a common physiological functional consequence of TnT-linked pathogenesis of FHC.

Although the detailed mechanisms by which single point mutations in TnT may cause Ca²⁺-sensitizing effects on force development are not clear at this time, the observed changes in the increased Ca²⁺ sensitivity of force development might be explained by one of the following ways or a combination of them; 1) increased Ca²⁺ affinity of TnC; 2) reduced inhibitory action of TnI, and 3) activation of the actomyosin interaction that indirectly leads to increased Ca²⁺ affinity of TnC. For example, we have previously demonstrated that the deletion mutant, E160, which increased Ca²⁺ sensitivity of both myofibrillar ATPase activity and force development of skinned fibers, did not affect the inhibitory action of TnI but enhanced neutralizing action of TnC (35, 36). Moreover, Tobacman et al. (37) show that the Tn·Tm complex containing the E160 TnT increased its affinity for Ca²⁺. These results strongly suggest that E160 increases Ca²⁺ sensitivity of myofibrillar ATPase activity and force development of skinned fibers by increasing Ca²⁺ affinity of TnC. Although we have not investigated in detail the effects of TnT mutations on the interaction between TnT and the other Tn subunits or Tm, we suggest that the specific amino acid substitutions and the region of TnT where the mutation occurs lead to distinct physiological consequences such as the increase in Ca²⁺ sensitivity and maximum force development. CD spectroscopy demonstrated variable secondary structures of TnT mutants in the presence of both low (0.3 M) and high (0.5 M) concentrations of NaF (Fig. 2). The WT and all TnT mutants had lower -helical content in the presence of 0.3 M NaF than in 0.5 M NaF (data not shown). This was not due to simple protein precipitation since centrifugation of these 0.3 M NaF samples at room temperature showed no pellets. The extent of -helical content reduction by decreasing NaF concentration was much greater for A104V mutant (40%) than for other TnT proteins (<23%). Interestingly, two independent reports from different laboratories show that a TnT fragment containing the Val-104 residue exhibited poor thermal stability of secondary structure compared with WT or the other mutants (30, 31). All TnT mutants showed similar secondary structure and the same amount of -helical content (70%, data not shown) when 40% 2,2,2-trifluoroethanol was added to stabilize the -helix and to closely mimic in vivo protein-protein interactions. This result implies that even though these mutations may not drastically alter the secondary structure of TnT alone under physiological conditions, the structural differences seen with TnT mutants under certain conditions may imply that mutations cause modified dynamic interactions between TnT and Tm, TnI, or TnC. However, it should be noted that these experiments are qualitative experiments since TnT would be unable to fold into its native conformation in the absence of the other troponin subunits.

Besides affecting Ca²⁺ sensitivity of force development, the near N-terminal mutants, R92L, R92W, R94L, and R130C, were shown to have decreased ability to displace Tn complex in the fibers. Palm et al. (30) show that mutations occurring in the region within 92–110 impair Tm binding or TnT enhancement of Tm binding to actin. Our results showing that R92L, R92W, and R94L had impaired exchangeability in fibers agree with their findings. Similar effects have been reported for the F110I mutant, which did not exchange well with endogenous porcine cardiac Tn complex (18). We showed that A104V did not reduce its exchange ability, whereas Palm et al. (30) demonstrate that it reduced the enhancement of Tm binding to actin but not its Tm-biding affinity. The R130C mutant also showed decreased exchangeability. The affinity of R130C for Tm or the thin filament, however, is unknown. Arg-130 is located in the essential TnT region (residues 112–136) for Tm binding (31); hence, it is expected that an Arg to Cys substitution at this position could reduce the binding affinity for Tm, resulting in the poor exchangeability seen with the mutant in this study.

In contrast, in the middle of the TnT molecule, mutants E163R and S179F and the C-terminal mutant E244D increased maximum force development of TnI·C-depleted fibers without reducing their TnT exchangeability. In the absence of TnI and TnC, E163R and S179F increased the maximum force development by 1520% compared with WT, whereas E244D increased maximum force development by >50%. Furthermore, the E244D-incorporated fibers showed higher maximum force development even after being reconstituted with the TnI·C complex than WT fibers, whereas the E163R and S179F fibers did not (or rather decreased the maximum force development slightly). These results together with the fact that these mutations occurred in the different structural and functional regions suggest that the mechanism by which E244D could potentiate the isometric force development might be different from the mechanism found for E163R or S179F. The region including residues Glu-163 and Ser-179 is near the end of the Tm binding rod region of TnT, and its detailed role in the regulation of force development is not known. It is possible that amino acid substitutions in this region alter thin filament activating states and/or the stability, although the observed potentiation of force occurred at sub-maximal Ca²⁺ concentrations. Yanaga et al. (38) report that E244D increased the maximum myofibrillar MgATPase activity, whereas Nakaura et al. (39) have shown that partial reconstitution of E244D into rabbit skinned cardiac fibers also potentiated the maximum force development before and after TnI·C reconstitution. These results are consistent with our current observations. It has been suggested that the region including Glu-244 in TnT interacts with TnI (40). The crystal structure of human cardiac Tn partial complex, including the entire TnC molecule, the N-terminal truncated fragment of TnI (residues 31–163), and the C-terminal half of TnT (residues 183–288), recently revealed by Takeda et al. (41), has demonstrated that residue Glu-244 is located in the middle of helix composed of residues 225–271, which interacts with the helix of TnI, including residues 90–136. Therefore, the mutation of Glu to Asp at position 244 would be expected to alter the interaction between TnT and TnI, leading to an abnormal contractile response to Ca²⁺. Nevertheless, we have observed the potentiated effect of this mutation on the isometric force development even in the absence or very little amount of TnI. These results indicate that the region including residue Glu-244 interacts with Tm and/or actin as well as TnI, and a substitution of Glu to Asp alters these interactions and possibly cross-bridge kinetics.

We have also studied the effect of these FHC-TnT mutations on the pH sensitivity of Ca²⁺-dependent force development. We have shown that all TnT-reconstituted fibers including WT decreased the Ca²⁺ sensitivity of force development as well as its maximum value when the pH was lowered from 7.0 to 6.5. However, three mutants, R92L, R92W, and R94L showed significantly smaller differences in the Ca²⁺ sensitivity of force measured at pH 7.0 and 6.5; their respective mean pCa₅₀ values were 0.42, 0.35, and 0.36 versus WT (mean pCa₅₀ = 0.54) or versus the other mutants (mean pCa₅₀ = 0.510.64). This suggests that these mutants demonstrate increased resistance to pH change. It has been previously reported by Morimoto et al. (32) that the I79N- and R92Q-TnT mutants reduce the Ca²⁺ desensitizing effect of pH. We have observed similar effects for the I79N-TnT mutation, which demonstrated an acidic pH resistance of the Ca²⁺ sensitivity of force in our transgenic mouse model (19). Moreover, as shown by Solaro et al. (42) skinned cardiac fibers from the transgenic mouse model of R92Q showed enhanced effects of increased Ca²⁺ sensitivity of force development at lower pH compared with that of nontransgenic mouse fibers. These results strongly indicated that a region including residues 79–94 in the HCTnT molecule could be involved in the pH-sensitive Ca²⁺ regulation of cardiac muscle contraction, and any mutations occurring in this region could lead to alterations in the acidic pH resistance. The His residue is often involved in pH-dependent functional perturbations because of its similar pK_a value to that of imidazole at physiological pH. For instance it has been demonstrated that one histidine residue in fast skeletal TnI is responsible for the difference in acidic pH resistance of skeletal versus cardiac muscles (43). There are two histidine residues, His-91 and His-109, that could be involved in this mechanism. Both of them are adjacent to residues involved in TnT-linked FHC, Arg-92 and Phe-110. NMR studies have revealed that the pK_a of the imidazole group, corresponding to the histidine residue in fast skeletal TnT (His-79) was around 7 in the presence of Tm (44), indicating that a fraction of the charged form of the imidazole group changes when the pH changes from pH 7.0 to 6.5 (50 and 78%, respectively). This difference may be an important factor for the pH-dependent Ca²⁺ regulation of force regulation. However, Nakaura et al. (39) report that F110I did not alter acidic pH resistance of Ca²⁺ sensitivity of force (39). Furthermore, we did not observe altered pH-dependent Ca²⁺ regulation by A104V, which is five amino acids away from His-109 and is closer to His-109 than Arg-92 or Arg-94. Therefore, we suspect that another residue, i.e. His-91, may be important as responsible for the increased acidic pH resistance by the TnT mutants, R92L, R92W, and R94L. To test this we created two new TnT mutants described below and examined their pH-dependent Ca²⁺ regulation of isometric force development (Fig. 5A). One mutant has a glutamine residue at position 91 instead of histidine (H91Q). We have chosen glutamine to neutralize the charge effect at position 91 and because glutamine corresponds to residue His-91 in the fast skeletal isoforms of most species. Another mutant, H91Q/R92W, carries one more mutation besides H91Q. Because the H91Q mutant fibers showed increased Ca²⁺ sensitivity of isometric force development at pH 7.0 (pCa₅₀ = 5.65 ± 0.01, n = 3) and demonstrated acidic pH resistance (pCa₅₀ = 0.31 ± 0.2) compared with WT it seems as if the His-91 residue is the one that is involved in the determination of pH-dependent Ca²⁺ regulation. H91Q/R92W exhibited a higher Ca²⁺ sensitivity of force development (pCa₅₀ = 5.84 ± 0.04, n = 3) and greater acidic pH resistance (pCa₅₀ = 0.25 ± 0.4) than H91Q or R92W and indicated that the Ca²⁺-sensitizing effect and the pH-desensitizing effect caused by H91Q and R92W substitutions were additive. These results strongly suggest that the cluster of positively charged residues of 91–94 (His-Arg-Lys-Arg) rather than a difference in the fraction of the charged imidazole group of His-91 between pH 7.0 and 6.5 per se is responsible for the determination of pH-dependent Ca²⁺ regulation of normal cardiac muscle contraction.

View larger version (14K): [in this window] [in a new window]   FIG. 5. Effect of the histidine to glutamine substitution at position 91 in HCTnT on the pH dependence of the Ca2+ sensitivity of force development. A histidine residue at position 91 in both HCTnT WT and R92W was replaced by glutamine and the pCa-force relationship of these two mutants, H91Q (circles) and H91Q/R92W (triangles), were increased at pH 7.0 (opened symbol) and pH 6.5 (closed symbols)(A). pCa50 at pH 7.0 (B) and pCa50 values (C) were compared with those values from WT- and R92W-reconstituted fibers by Turky-Kramer's multiple-comparison test. *, p < 0.05; **, p < 0.01; ***, p < 0.001. n.s., not significant.

In conclusion, we have observed multiple functional consequences from different FHC-TnT mutations that occur in different functional regions of the HCTnT molecule. These results strongly suggest that various mutations alter contractile properties in different ways and that these differences may contribute to the molecular pathogenesis of TnT-linked FHC. Because of the limited amount of clinical data available, complicated backgrounds such as environmental factors or haplotype (49) or the possibility of additional mutations, including homozygous mutations (24, 50, 51), it is difficult to characterize phenotypes precisely. However, results from in vitro studies together with animal models might be helpful for elucidating the molecular mechanisms of the effect of these mutations on cardiac function.

	FOOTNOTES

 
^* This work was supported in part by National Institutes of Health Grants HL-42325 and HL-674154. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by an American Hearth Association postdoctoral fellowship (Florida/Puerto Rico affiliate).

To whom correspondence should be addressed: Dept. of Molecular and Cellular Pharmacology, University of Miami School of Medicine, 1600 N. W. 10th Ave., Miami, FL 33136. Tel.: 305-243-5874; Fax: 305-324-6024; E-mail: jdpotter{at}miami.edu.

¹ The abbreviations used are: Tn, troponin; HCTnT, human cardiac troponin T; TnI, troponin I; TnC, troponin C; Tm; tropomyosin; FHC, familial hypertrophic cardiomyopathy; MES, 2-[N-morpholino]ethanesulfonic acid; SCD, sudden cardiac death; WT, wild type.

	ACKNOWLEDGMENTS

 
We thank Drs. Danuta Szczesna-Cordary and Aldrin V. Gomes for critical reading of the manuscript.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Zot, A. S., and Potter, J. D. (1987) Annu. Rev. Biophys. Biophys. Chem. 16, 535–559[CrossRef][Medline] [Order article via Infotrieve]
2. Ohtsuki, I., Maruyama, K., and Ebashi, S. (1986) Adv. Protein Chem. 38, 1–67[Medline] [Order article via Infotrieve]
3. Perry, S. V. (1998) J. Muscle Res. Cell Motil. 19, 575–602[CrossRef][Medline] [Order article via Infotrieve]
4. Geisterfer-Lowrance, A. A., Kass, S., Tanigawa, G., Vosberg, H. P., McKenna, W., Seidman, C. E., and Seidman, J. G. (1990) Cell 62, 999–1006[CrossRef][Medline] [Order article via Infotrieve]
5. Poetter, K., Jiang, H., Hassanzadeh, S., Master, S. R., Chang, A., Dalakas, M. C., Rayment, I., Sellers, J. R., Fananapazir, L., and Epstein, N. D. (1996) Nat. Genet. 13, 63–69[CrossRef][Medline] [Order article via Infotrieve]
6. Bonne, G., Carrier, L., Bercovici, J., Cruaud, C., Richard, P., Hainque, B., Gautel, M., Labeit, S., James, M., Beckmann, J., et al. (1995) Nat. Genet. 11, 438–440[CrossRef][Medline] [Order article via Infotrieve]
7. Watkins, H., Conner, D., Thierfelder, L., Jarcho, J. A., MacRae, C., McKenna, W. J., Maron, B. J., Seidman, J. G., and Seidman, C. E. (1995) Nat. Genet. 11, 434–437[CrossRef][Medline] [Order article via Infotrieve]
8. Mogensen, J., Klausen, I. C., Pedersen, A. K., Egeblad, H., Bross, P., Kruse, T. A., Gregersen, N., Hansen, P. S., Baandrup, U., and Borglum, A. D. (1999) J. Clin. Invest. 103, 39–43[Medline] [Order article via Infotrieve]
9. Thierfelder, L., Watkins, H., MacRae, C., Lamas, R., McKenna, W., Vosberg, H. P., Seidman, J. G., and Seidman, C. E. (1994) Cell 77, 701–712[CrossRef][Medline] [Order article via Infotrieve]
10. Kimura, A., Harada, H., Park, J. E., Nishi, H., Satoh, M., Takahashi, M., Hiroi, S., Sasaoka, T., Ohbuchi, N., Nakamura, T., Koyanagi, T., Hwang, T. H., Choo, J. A., Chung, K. S., Hasegawa, A., Nagai, R., Okazaki, O., Nakamura, H., Matsuzaki, M., Sakamoto, T., Toshima, H., Koga, Y., Imaizumi, T., and Sasazuki, T. (1997) Nat. Genet. 16, 379–382[CrossRef][Medline] [Order article via Infotrieve]
11. Hoffmann, B., Schmidt-Traub, H., Perrot, A., Osterziel, K. J., and Gessner, R. (2001) Hum. Mutat. 17, 524[Medline] [Order article via Infotrieve]
12. Satoh, M., Takahashi, M., Sakamoto, T., Hiroe, M., Marumo, F., and Kimura, A. (1999) Biochem. Biophys. Res. Commun. 262, 411–417[CrossRef][Medline] [Order article via Infotrieve]
13. Marian, A. J., Salek, L., and Lutucuta, S. (2001) Minn. Med. 92, 435–451
14. Gomes, A. V., Barnes, J. A., Harada, K., and Potter, J. D. (2004) Mol. Cell. Biochem., in press
15. Varnava, A. M., Elliott, P. M., Baboonian, C., Davison, F., Davies, M. J., and McKenna, W. J. (2001) Circulation 104, 1380–1384[Abstract/Free Full Text]
16. Hernandez, O. M., Housmans, P. R., and Potter, J. D. (2001) J. Appl. Physiol. 90, 1125–1136[Abstract/Free Full Text]
17. Knollmann, B. C., and Potter, J. D. (2001) Trends Cardiovas. Med. 11, 206–212[CrossRef][Medline] [Order article via Infotrieve]
18. Szczesna, D., Zhang, R., Zhao, J., Jones, M., Guzman, G., and Potter, J. D. (2000) J. Biol. Chem. 275, 624–630[Abstract/Free Full Text]
19. Miller, T., Szczesna, D., Housmans, P. R., Zhao, J., de Freitas, F., Gomes, A. V., Culbreath, L., McCue, J., Wang, Y., Xu, Y., Kerrick, W. G., and Potter, J. D. (2001) J. Biol. Chem. 276, 3743–3755[Abstract/Free Full Text]
20. Knollmann, B. C., Blatt, S. A., Horton, K., de Freitas, F., Miller, T., Bell, M., Housmans, P. R., Weissman, N. J., Morad, M., and Potter, J. D. (2001) J. Biol. Chem. 276, 10039–10048[Abstract/Free Full Text]
21. Moolman, J. C., Corfield, V. A., Posen, B., Ngumbela, K., Seidman, C., Brink, P. A., and Watkins, H. (1997) J. Am. Coll. Cardiol. 29, 549–555[Abstract]
22. Varnava, A., Baboonian, C., Davison, F., de Cruz, L., Elliott, P. M., Davies, M. J., and McKenna, W. J. (1999) Heart 82, 621–624[Abstract/Free Full Text]
23. Nakajima-Taniguchi, C., Matsui, H., Fujio, Y., Nagata, S., Kishimoto, T., and Yamauchi-Takihara, K. (1997) J. Mol. Cell. Cardiol. 29, 839–843[CrossRef][Medline] [Order article via Infotrieve]
24. Ho, C. Y., Lever, H. M., DeSanctis, R., Farver, C. F., Seidman, J. G., and Seidman, C. E. (2000) Circulation 102, 1950–1955[Abstract/Free Full Text]
25. Forissier, J. F., Carrier, L., Farza, H., Bonne, G., Bercovici, J., Richard, P., Hainque, B., Townsend, P. J., Yacoub, M. H., Faure, S., Dubourg, O., Millaire, A., Hagege, A. A., Desnos, M., Komajda, M., and Schwartz, K. (1996) Circulation 94, 3069–3073[Abstract/Free Full Text]
26. Koga, Y., Toshima, H., Kimura, A., Harada, H., Koyanagi, T., Nishi, H., Nakata, M., and Imaizumi, T. (1996) J. Card. Fail. 2, 97–103
27. Watkins, H., McKenna, W. J., Thierfelder, L., Suk, H. J., Anan, R., O'Donoghue, A., Spirito, P., Matsumori, A., Moravec, C. S., Seidman, J. G., and Seidman, C. E. (1995) N. Engl. J. Med. 332, 1058–1064[Abstract/Free Full Text]
28. Chen, Y. H., and Yang, J. T. (1971) Biochem. Biophys. Res. Commun. 44, 1285–1291[CrossRef][Medline] [Order article via Infotrieve]
29. Hatakenaka, M., and Ohtsuki, I. (1992) Eur. J. Biochem. 205, 985–993[Medline] [Order article via Infotrieve]
30. Palm, T., Graboski, S., Hitchcock-DeGregori, S. E., and Greenfield, N. J. (2001) Biophys. J. 81, 2827–2837[Medline] [Order article via Infotrieve]
31. Hinkle, A., and Tobacman, L. S. (2003) J. Biol. Chem. 278, 506–513[Abstract/Free Full Text]
32. Morimoto, S., Yanaga, F., Minakami, R., and Ohtsuki, I. (1998) Am. J. Physiol. 275, C200–C207
33. Harada, K., Szczesna, D., Hernandez, O. M., and Potter, J. D. (2002) Biophys. J. 28, 391 (abstr.)
34. Lin, D., Bobkova, A., Homsher, E., and Tobacman, L. S. (1996) J. Clin. Invest. 97, 2842–2848[Medline] [Order article via Infotrieve]
35. Harada, K., Takahashi-Yanaga, F., Minakami, R., Morimoto, S., and Ohtsuki, I. (2000) J. Biochem. (Tokyo) 127, 263–268[Abstract/Free Full Text]
36. Morimoto, S., Lu, Q. W., Harada, K., Takahashi-Yanaga, F., Minakami, R., Ohta, M., Sasaguri, T., and Ohtsuki, I. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 913–918[Abstract/Free Full Text]
37. Tobacman, L. S., Lin, D., Butters, C., Landis, C., Back, N., Pavlov, D., and Homsher, E. (1999) J. Biol. Chem. 274, 28363–28370[Abstract/Free Full Text]
38. Yanaga, F., Morimoto, S., and Ohtsuki, I. (1999) J. Biol. Chem. 274, 8806–8812[Abstract/Free Full Text]
39. Nakaura, H., Yanaga, F., Ohtsuki, I., and Morimoto, S. (1999) J. Biochem. (Tokyo) 126, 457–460[Abstract/Free Full Text]
40. Stefancsik, R., Jha, P. K., and Sarkar, S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 957–962[Abstract/Free Full Text]
41. Takeda, S., Yamashita, A., Maeda, K., and Maeda, Y. (2003) Nature 424, 35–41[CrossRef][Medline] [Order article via Infotrieve]
42. Solaro, R. J., Varghese, J., Marian, A. J., and Chandra, M. (2002) Basic Res. Cardiol. 97, Suppl. 1, 102–110
43. Dargis, R., Pearlstone, J. R., Barrette-Ng, I., Edwards, H., and Smillie, L. B. (2002) J. Biol. Chem. 277, 34662–34665[Abstract/Free Full Text]
44. Brisson, J. R., Golosinska, K., Smillie, L. B., and Sykes, B. D. (1986) Biochemistry 25, 4548–4555[CrossRef][Medline] [Order article via Infotrieve]
45. Donaldson, S. K., Hermansen, L., and Bolles, L. (1978) Pfluegers Arch. Eur. J. Physiol. 376, 55–65[CrossRef][Medline] [Order article via Infotrieve]
46. Fabiato, A., and Fabiato, F. (1978) J. Physiol. 276, 233–255[Abstract/Free Full Text]
47. Lynch, G. S., and Williams, D. A. (1994) Exp. Physiol. 79, 47–57[Abstract]
48. Morimoto, S., Harada, K., and Ohtsuki, I. (1999) J. Biochem. (Tokyo) 126, 121–129[Abstract/Free Full Text]
49. Moolman-Smook, J. C., De Lange, W. J., Bruwer, E. C., Brink, P. A., and Corfield, V. A. (1999) Am. J. Hum. Genet. 65, 1308–1320[CrossRef][Medline] [Order article via Infotrieve]
50. Richard, P., Isnard, R., Carrier, L., Dubourg, O., Donatien, Y., Mathieu, B., Bonne, G., Gary, F., Charron, P., Hagege, M., Komajda, M., Schwartz, K., and Hainque, B. (1999) J. Med. Genet. 36, 542–545[Abstract/Free Full Text]
51. Lin, T., Ichihara, S., Yamada, Y., Nagasaka, T., Ishihara, H., Nakashima, N., and Yokota, M. (2000) Cardiology 93, 155–162[CrossRef][Medline] [Order article via Infotrieve]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				D. Dweck, N. Hus, and J. D. Potter Challenging Current Paradigms Related to Cardiomyopathies: ARE CHANGES IN THE Ca2+ SENSITIVITY OF MYOFILAMENTS CONTAINING CARDIAC TROPONIN C MUTATIONS (G159D AND L29Q) GOOD PREDICTORS OF THE PHENOTYPIC OUTCOMES? J. Biol. Chem., November 28, 2008; 283(48): 33119 - 33128. [Abstract] [Full Text] [PDF]

				Y. Wen, J. R. Pinto, A. V. Gomes, Y. Xu, Y. Wang, Y. Wang, J. D. Potter, and W. G. L. Kerrick Functional Consequences of the Human Cardiac Troponin I Hypertrophic Cardiomyopathy Mutation R145G in Transgenic Mice J. Biol. Chem., July 18, 2008; 283(29): 20484 - 20494. [Abstract] [Full Text] [PDF]

				B. Liang, F. Chung, Y. Qu, D. Pavlov, T. E. Gillis, S. B. Tikunova, J. P. Davis, and G. F. Tibbits Familial hypertrophic cardiomyopathy-related cardiac troponin C mutation L29Q affects Ca2+ binding and myofilament contractility Physiol Genomics, April 1, 2008; 33(2): 257 - 266. [Abstract] [Full Text] [PDF]

				M. Revera, L. van der Merwe, M. Heradien, A. Goosen, V. A. Corfield, P. A. Brink, and J. C. Moolman-Smook Troponin T and {beta}-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy Cardiovasc Res, March 1, 2008; 77(4): 687 - 694. [Abstract] [Full Text] [PDF]

				S. Morimoto Sarcomeric proteins and inherited cardiomyopathies Cardiovasc Res, March 1, 2008; 77(4): 659 - 666. [Abstract] [Full Text] [PDF]

				J. R. Pinto, M. S. Parvatiyar, M. A. Jones, J. Liang, and J. D. Potter A Troponin T Mutation That Causes Infantile Restrictive Cardiomyopathy Increases Ca2+ Sensitivity of Force Development and Impairs the Inhibitory Properties of Troponin J. Biol. Chem., January 25, 2008; 283(4): 2156 - 2166. [Abstract] [Full Text] [PDF]

				A. Thawornkaiwong, J. Pantharanontaga, and J. Wattanapermpool Hypersensitivity of myofilament response to Ca2+ in association with maladaptation of estrogen-deficient heart under diabetes complication Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R844 - R851. [Abstract] [Full Text] [PDF]

				B. R. Ertz-Berger, H. He, C. Dowell, S. M. Factor, T. E. Haim, S. Nunez, S. D. Schwartz, J. S. Ingwall, and J. C. Tardiff Changes in the chemical and dynamic properties of cardiac troponin T cause discrete cardiomyopathies in transgenic mice PNAS, December 13, 2005; 102(50): 18219 - 18224. [Abstract] [Full Text] [PDF]

				O. M. Hernandez, D. Szczesna-Cordary, B. C. Knollmann, T. Miller, M. Bell, J. Zhao, S. G. Sirenko, Z. Diaz, G. Guzman, Y. Xu, et al. F110I and R278C Troponin T Mutations That Cause Familial Hypertrophic Cardiomyopathy Affect Muscle Contraction in Transgenic Mice and Reconstituted Human Cardiac Fibers J. Biol. Chem., November 4, 2005; 280(44): 37183 - 37194. [Abstract] [Full Text] [PDF]

				G. Venkatraman, A. V. Gomes, W. G. L. Kerrick, and J. D. Potter Characterization of Troponin T Dilated Cardiomyopathy Mutations in the Fetal Troponin Isoform J. Biol. Chem., May 6, 2005; 280(18): 17584 - 17592. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 279/15/14488    most recent M309355200v2 M309355200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harada, K. Articles by Potter, J. D. Search for Related Content PubMed PubMed Citation Articles by Harada, K. Articles by Potter, J. D. Social Bookmarking                      What's this?